Literature DB >> 1977083

Inhibition by dopamine of (Na(+)+K+)ATPase activity in neostriatal neurons through D1 and D2 dopamine receptor synergism.

A M Bertorello1, J F Hopfield, A Aperia, P Greengard.   

Abstract

The (Na(+)+K+)ATPase, an integral membrane protein located in virtually all animal cells, couples the hydrolysis of ATP to the countertransport of Na+ and K+ ions across the plasma membrane. In neurons, a large portion of cellular energy is expended by this enzyme to maintain the ionic gradients that underlie resting and action potentials. Although neurotransmitter regulation of the enzyme in brain has been reported, such regulation has been characterized either as a nonspecific phenomenon or as an indirect effect of neurotransmitter-induced changes in ionic gradients. We report here that the neurotransmitter dopamine, through a synergistic effect on D1 and D2 receptors, inhibits the (Na(+)+K+)ATPase activity of isolated striatal neurons. Our data provide unequivocal evidence for regulation by a neurotransmitter of a neuronal ion pump. They also demonstrate that synergism between D1 and D2 receptors, which underlies many of the electrophysical and behavioural effects of dopamine in the mammalian brain, can occur on the same neuron. In addition, the results support the possibility that dopamine and other neurotransmitters can regulate neuronal excitability through the novel mechanism of pump inhibition.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1977083     DOI: 10.1038/347386a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  56 in total

1.  Synergistically interacting dopamine D1 and NMDA receptors mediate nonvesicular transporter-dependent GABA release from rat striatal medium spiny neurons.

Authors:  A N Schoffelmeer; L J Vanderschuren; T J De Vries; F Hogenboom; G Wardeh; A H Mulder
Journal:  J Neurosci       Date:  2000-05-01       Impact factor: 6.167

2.  Dopamine receptor subtypes colocalize in rat striatonigral neurons.

Authors:  D J Surmeier; J Eberwine; C J Wilson; Y Cao; A Stefani; S T Kitai
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

3.  Calcineurin mediates alpha-adrenergic stimulation of Na+,K(+)-ATPase activity in renal tubule cells.

Authors:  A Aperia; F Ibarra; L B Svensson; C Klee; P Greengard
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

Review 4.  In search of synaptosomal Na+,K(+)-ATPase regulators.

Authors:  G Rodríguez de Lores Arnaiz
Journal:  Mol Neurobiol       Date:  1992       Impact factor: 5.590

Review 5.  Dopamine receptor genes: new tools for molecular psychiatry.

Authors:  H B Niznik; H H Van Tol
Journal:  J Psychiatry Neurosci       Date:  1992-10       Impact factor: 6.186

Review 6.  Na(+),K (+)-ATPase as a docking station: protein-protein complexes of the Na(+),K (+)-ATPase.

Authors:  Linda Reinhard; Henning Tidow; Michael J Clausen; Poul Nissen
Journal:  Cell Mol Life Sci       Date:  2012-06-14       Impact factor: 9.261

7.  Calcium signaling by dopamine D5 receptor and D5-D2 receptor hetero-oligomers occurs by a mechanism distinct from that for dopamine D1-D2 receptor hetero-oligomers.

Authors:  Christopher H So; Vaneeta Verma; Mohammad Alijaniaram; Regina Cheng; Asim J Rashid; Brian F O'Dowd; Susan R George
Journal:  Mol Pharmacol       Date:  2009-01-26       Impact factor: 4.436

8.  Dopamine D2-like receptor-mediated opening of K+ channels in opossum kidney cells.

Authors:  Pedro Gomes; Patrício Soares-da-Silva
Journal:  Br J Pharmacol       Date:  2003-03       Impact factor: 8.739

Review 9.  Renal dopamine and angiotensin II receptor signaling in age-related hypertension.

Authors:  Gaurav Chugh; Indira Pokkunuri; Mohammad Asghar
Journal:  Am J Physiol Renal Physiol       Date:  2012-10-24

10.  Cyclic AMP mediates inhibition of the Na(+)-K+ electrogenic pump by serotonin in tactile sensory neurones of the leech.

Authors:  S Catarsi; R Scuri; M Brunelli
Journal:  J Physiol       Date:  1993-03       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.